U.S. FDA Approves Canagliflozin (TA-7284) for the Treatment of Adult Patients with Type 2 Diabetes

Osaka, Japan, April 1, 2013---Janssen Pharmaceuticals, Inc. (Raritan, NJ, US) announced on March 29, 2013, that the company obtained NDA approval in the United States for TA-7284 (generic name, canagliflozin), selective sodium glucose co-transporter 2 (SGLT2) inhibitors, which the company has developed as a treatment of adult patients with type 2 diabetes mellitus. It is the first in a new class of type 2 diabetes medications available in the United States.

TA-7284 was discovered by Tanabe Seiyaku Ltd. (present Mitsubishi Tanabe Pharma Corporation), and was licensed out to Janssen to be developed and marketed in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand, and parts of Asia excluding Japan. In Japan, Mitsubishi Tanabe Pharma is currently conducting a development (Phase 3) for type 2 diabetes mellitus, and actively pursuing the development so as to submit a manufacturing and marketing approval to the Ministry of Health, Labor and Welfare at the earliest possible time.

By providing new treatment option for type 2 diabetes mellitus, Mitsubishi Tanabe Pharma hopes to support patients, who are combating this disease.

<Media enquiry>
Corporate Communications Department
Phone: +81 6-6205-5211